Multinostics
Developer of a portable, integrated ocular testing system that combines hardware and software to detect early-stage Alzheimer’s disease using retinal biomarkers. The organization conducts research on retinal imaging and electrophysiology, builds AI models that integrate static and dynamic ocular metrics, and publishes peer-reviewed studies and patent applications related to eye-based biomarkers for cognitive impairment.
Industries
Nr. of Employees
small (1-50)
Multinostics
Pembroke Pines, Florida, United States, North America
Products
Portable ocular testing device for early detection of Alzheimer’s disease
An integrated, portable eye-testing system combining device hardware with software and AI algorithms to capture retinal imaging and electrophysiological signals for early detection of Alzheimer’s disease.
Portable ocular testing device for early detection of Alzheimer’s disease
An integrated, portable eye-testing system combining device hardware with software and AI algorithms to capture retinal imaging and electrophysiological signals for early detection of Alzheimer’s disease.
Services
AI-assisted screening platform development for cognitive impairment biomarkers
Research and development of an AI-assisted platform that integrates multiple ocular biomarkers to screen for mild cognitive impairment due to Alzheimer’s disease.
AI-assisted screening platform development for cognitive impairment biomarkers
Research and development of an AI-assisted platform that integrates multiple ocular biomarkers to screen for mild cognitive impairment due to Alzheimer’s disease.
Expertise Areas
- Digital health and AI diagnostics
- Retinal imaging and analysis
- Biomarker discovery and validation
- Translational research for neurodegenerative disease
Key Technologies
- AI-driven diagnostics
- Electroretinography (ERG)
- Retinal vascular fractal analysis
- Retinal imaging (including OCT referenced in publications)